
Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.

Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.
Founded: 2017
Headquarters: Boston
Focus: Cells-to-software synthetic biology platform for designing and manufacturing biologics and cell/gene therapies
Product highlights: CHO Edge, LV Edge, AAV Edge, Kernel (genetic design software)
Funding: $205,000,000 total (latest listed: Series B on 2023-01-05)
Synthetic biology and biomanufacturing for next-generation therapeutics (biologics, cell and gene therapies).
2017
Biotechnology Research
$4.7M
Reported seed funding amount per press coverage.
“Backed by institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, Fidelity Management & Research Company, Casdin Capital, DCVC, AME Cloud Ventures, KdT Ventures, and Pillar VC.”
| Company |
|---|
Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We're developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics.
We are seeking a Scientist, Biologics Cell Line Development to join our team in Boston, MA and help push the boundaries of biotherapeutic cell line development. This role is for a technical expert who will conduct CHO-based cell line engineering for biologic therapeutics, design complex experimental approaches to improve our workflows and systems, coordinate project efforts, and mentor junior scientists.
The successful candidate will also work closely with Asimov’s synthetic biology and process development teams. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology startup and help build the future of biological engineering.
We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.